Sage’s Dalzanemdor Shows Effect in Huntington’s Study, Analysts Say Results ‘Underwhelming’

Sage Therapeutics announced Tuesday that its oral NMDA receptor dalzanemdor showed a slight numerical improvement in a small Phase II Huntington’s disease trial, while acknowledging the study was not designed to demonstrate a statistically significant difference between the drug candidate and placebo.